Cytochrome P450 Enzymes: |
---|
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.372E-14 | 7.342E-10 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.568E-13 | 5.906E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.710E-12 | 1.180E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.528E-12 | 1.280E-08 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.161E-10 | 3.160E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0020037; heme binding | 3.586E-10 | 7.099E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.383E-09 | 1.940E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.515E-09 | 1.940E-06 | CYP1A2, CYP2C9, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.067E-09 | 2.500E-06 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 8.300E-08 | 6.232E-05 | CYP1A2, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 6.647E-07 | 4.257E-04 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 1.203E-06 | 6.549E-04 | ALDH1A1, CYP1A1, CYP1B1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.688E-06 | 8.547E-04 | CYP1A1, CYP3A4 |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 2.517E-06 | 1.191E-03 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, RAB9A |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.374E-06 | 1.527E-03 | CYP1A1, CYP1A2 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 5.621E-06 | 2.400E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 8.428E-06 | 3.463E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 1.179E-05 | 4.586E-03 | CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 1.572E-05 | 6.005E-03 | CYP1A1, CYP1A2 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.916E-11 | 5.748E-10 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 9.076E-10 | 1.361E-08 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.645E-09 | 1.645E-08 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.811E-09 | 3.608E-08 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.721E-07 | 8.603E-07 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 8.485E-08 | 5.091E-07 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 3.316E-06 | 1.421E-05 | CYP1A2; CYP1A1; CYP1B1 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.720E-04 | 6.449E-04 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; CYP2C19; CYP3A4 |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 6.299E-04 | 2.100E-03 | CYP1A1; CYP1B1 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 9.673E-04 | 2.638E-03 | CYP2C9; CYP2C19 |
hsa05130 | Pathogenic Escherichia coli infection_Homo sapiens_hsa05130 | 7.620E-04 | 2.286E-03 | TUBB3; TUBB1 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.266E-03 | 3.166E-03 | ABCB1; CYP3A4 |
hsa04540 | Gap junction_Homo sapiens_hsa04540 | 1.936E-03 | 4.468E-03 | TUBB3; TUBB1 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.112E-03 | 6.668E-03 | CYP2C9; CYP2C19 |
hsa04145 | Phagosome_Homo sapiens_hsa04145 | 5.791E-03 | 1.086E-02 | TUBB3; TUBB1 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 2.031E-02 | 3.585E-02 | ABCB1; CYP1B1 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 3.745E-03 | 7.490E-03 | CYP1A2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
C00-D49: Neoplasms | Cancer | C00-C96 | ABCB1; HIF1A |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | ABCB1; TUBB1; HIF1A |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | ABCB1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
C00-D49: Neoplasms | Lung cancer | C33-C34 | TUBB1 |
C00-D49: Neoplasms | Ovarian cancer | C56 | ABCB1 |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1; CYP2C9 |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |